Business
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -
About this update from C4 Therapeutics, Inc.
[{"type":"image","alt":"C4 Therapeutics, Inc.","displaySize":"","headline":null,"caption":"C4 Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/octIZ3xbuMh0O2fgF.yqVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85","width":300,"height":45}},"lazy":false},{"type":"text","content":" Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg","length":102,"tagName":"p"},{"type":"text","content":"Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026","length":90,"tagName":"p"},{"type":"text","content":"Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways","length":175,"tagName":"p"},{"type":"text","content":"Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points","length":79,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today outlined milestones through 2028 and highlighted recent achievements.","length":275,"tagName":"p"},{"type":"text","content":"“We begin 2026 with compelling opportunities ahead, anchored by cemsidomide’s path to become a foundational medicine for multiple myeloma by reaching patients across multiple lines of therapy. As we prepare to initiate two cemsidomide trials in the coming months, we believe the emerging data exploring the class in combination with BiTE therapies derisks our strategy to rapidly advance cemsidomide through registrational development,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We are equally excited about our new discovery strategy that leverages a decade of learnings in the TPD field as well as the strengths of our platform to address unmet needs for inflammation, neuro-inflammation and neuro-degenerative diseases by degrading novel targets that modulate validated inflammatory pathways. ...